Pediatric Bone Marrow Transplant News
2013 | 2012 | 2011 | 2010 | 2009 |
Mortality rates for many childhood cancers have declined by more than 50 percent over the past three decades.
But this overall positive trend can’t hide the stubbornly high mortality rates still seen in certain pediatric malignancies. Much of our highest-powered pediatric research in bone marrow transplantation (BMT), genomics, and immunotherapy is now aimed at these lethal cancers.
This issue includes articles about progress on two fronts in treating the most challenging pediatric malignancies:
- Fighting Leukemia with Engineered T Cells
- New Targeted Radiation for High-Risk Neuroblastoma
For many children with high-risk or chemotherapy-refractory leukemia, allogeneic hematopoietic stem cell transplantation is the standard of care. Over the past decade, transplantation techniques have advanced and more patients than ever are now completely cured of their cancer. But the procedure is still an ordeal for many young patients and their families, often involving a long tense wait for a bone marrow match, substantial complications, and no guarantee of success.
That’s why researchers here at Seattle Cancer Care Alliance (SCCA) and Fred Hutchinson Cancer Research Center (FHCRC) are continually refining transplantation methods for leukemia. In this issue learn about our emerging strategies that promise to improve transplant outcomes in three
- Ensuring Patient Access
- Reducing the Risk of Graft Versus Host Disease (GVHD)
- Improving Treatment of Relapse
Since the first successful bone marrow transplants of the 1970s, much has been learned about the elements of care required for long-term effectiveness and safety. Today, we have transplant protocols suited for pediatric patients with all types of blood disorders and varying degrees of donor match. We have new treatments to boost survival and quality of life. And, based on three decades of research on some truly inspirational patients, we have a storehouse of evidence to guide the next decade of pediatric transplantation.
In this issue, read about:
Every year, stem cell transplants for children are getting better. We now have safer preparative regimens, novel alternative donor sources, and dozens of carefully designed protocols to help overcome barriers to using mismatched or partially matched donor cells.
In this issue, read about Treosulfan, a drug being tested as a reduced-toxicity conditioning agent, and see a complete list of marrow and stem cell transplant trials open to children.Related Diseases: Blood Disorders, Bone Marrow Failure Diseases, Bone Marrow Transplant, Bone Marrow Transplant - Children , Fanconi Anemia
Cord blood transplantation has grown from just five transplants in 2005 to 44 in 2009 in both pediatric and adult patients at Seattle Cancer Care Alliance. This issue focuses on this burgeoning stem cell resource and the exciting life-saving clinical trials being conducted here. Read these interesting articles in this issue:
In this issue, read about
Treatment for Bone Marrow Failure Diseases Brings Hope
Diagnosing a child with bone marrow failure syndromes often begins early in life. Seattle Cancer Care Alliance and Seattle Children’s are the referral center for children and adults with bone marrow failure syndromes in the Pacific Northwest.
BMT and Gene Therapy
Researchers at Seattle Children’s, Fred Hutchinson Cancer Research Center, and University of Washington are working to optimize bone marrow transplant and gene therapy for treatment of bone marrow failure diseases.
North American Shwachman-Diamond Syndrome Registry
The new North American Shwachman-Diamond Syndrome Registry is based at Fred Hutchinson Cancer Research Center.
In this issue, SCCA is proud to announce that its Transplant Program ranks First in one-year survival rates, according to an independent report.
Read more about pediatric transplant research at SCCA for Aplastic Anemia, non-myeloablative transplants, and transplants for bone marrow failure and immune deficiency diseases.
Meet Lauri Burroughs, MD who specializes in bone marrow transplantation at Seattle Cancer Care Alliance and Seattle Children’s.
Outcomes Studies Reveal Patients’ Post-Transplant Experiences
In this issue, topics covered include:
- Unraveling Chronic Graft-vs.-Host Disease
- One-Year Follow-Up: What Is It Good For?
- Increased Risk for Second Cancer After Transplant
- Examining the Many Dimensions of Post-Transplant Life
- The Link Between Metabolic Syndrome and Leukemia
- Does Transplant Raise Risk of Heart Problems?
- Using Imatinib and Nilotinib to Prevent Post-Transplant Relapse
2013 | 2012 | 2011 | 2010 | 2009 |